Viridian Therapeutics, Inc.\DE business relationships
Companies named in Viridian Therapeutics, Inc.\DE’s 10-K filed 2026-02-26, and public companies whose annual reports name Viridian Therapeutics, Inc.\DE. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.6 / 10
- AI naming
- <1 / 100 Top 10% in its category
- Agent readiness
- 30 / 100
- AI adoption
- 0 / 100
Named in Viridian Therapeutics, Inc.\DE’s annual report 10
“In January 2025, Zenas BioPharma sublicensed their rights under the license agreement to Zai Lab (Hong Kong) Limited ("Zai Lab") and assigned to them the manufacturing development and supply agreement.” SEC filing
“Collaboration revenue - related parties for the years ended December 31, 2025 and 2024 was attributable to our collaboration agreement with Zenas BioPharma and the Side Agreement and MTA with Zai Lab.” SEC filing
“In January 2025, Zenas BioPharma sublicensed their rights under the license agreement to Zai Lab and assigned the Manufacturing Development and Supply Agreement to Zai Lab in connection with the sublicense transaction.” SEC filing
“Development and License Agreement with Enable Injections, Inc.” SEC filing
“License Agreement with ImmunoGen, Inc.” SEC filing
“As described below, we licensed the right to develop, manufacture and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China to Zenas BioPharma (Cayman) Limited (now Zenas BioPharma, Inc., their successor in interest, "Zenas BioPharma").” SEC filing
“License Agreement with Zenas BioPharma” SEC filing
“Collaboration revenue - related parties for the years ended December 31, 2025 and 2024 was attributable to our collaboration agreement with Zenas BioPharma and the Side Agreement and MTA with Zai Lab.” SEC filing
“In May 2022, we entered into a manufacturing development and supply agreement with Zenas BioPharma to manufacture and supply, or have manufactured and supplied, clinical drug product for development purposes.” SEC filing
“As of January 2026, recruitment ongoing in China only and ex-China rights were licensed to Yarrow Bioscience in December 2025.” SEC filing
Companies whose annual reports name Viridian Therapeutics, Inc.\DE 1
“License Agreement with Viridian Therapeutics, Inc.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.